About the Innovative Medicines Initiative – Key Features

A key feature of the IMI project is the way different stakeholders work together across Europe (EU-25, Associated States and Candidate Countries), establishing a new type of collaboration between industry, academia, regulators, health-care professionals and patients. The potential of IMI to create a new biomedical R&D paradigm is based on:

• involving all stakeholders, including regulatory authorities, more closely in the enhancement of the biomedical R&D process,
• increasing the systematic use of biomarkers,
  applying innovative technologies such as genomics and proteomics in combination with appropriate knowledge management capabilities,
• facilitating a smooth transition from basic science to clinical research and regulatory standards, and
• a lean organisation with concrete and achievable objectives.
  

About the Innovative Medicines Initiative (IMI) - Key Drivers

IMI was granted the status of Joint Undertaking (Joint Technology Initiative (JTI) by the European Council and European Parliament in December 2007.

The key drivers underpinning the organisational structure of IMI are to:

• foster a collaborative environment,
• foster scientific excellence,
• optimise administrative processes, and
• ensure transparency.